JP2023549115A5 - - Google Patents
Info
- Publication number
- JP2023549115A5 JP2023549115A5 JP2023526961A JP2023526961A JP2023549115A5 JP 2023549115 A5 JP2023549115 A5 JP 2023549115A5 JP 2023526961 A JP2023526961 A JP 2023526961A JP 2023526961 A JP2023526961 A JP 2023526961A JP 2023549115 A5 JP2023549115 A5 JP 2023549115A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- rnai construct
- lpa rnai
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024192703A JP2025016670A (ja) | 2020-11-05 | 2024-11-01 | アテローム硬化性心血管疾患をＬＰＡ標的ＲＮＡｉ構築体により処置する方法 |
| JP2026071764A JP2026116347A (ja) | 2020-11-05 | 2026-04-23 | アテローム硬化性心血管疾患をＬＰＡ標的ＲＮＡｉ構築体により処置する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110309P | 2020-11-05 | 2020-11-05 | |
| US63/110,309 | 2020-11-05 | ||
| PCT/US2021/058012 WO2022098841A1 (en) | 2020-11-05 | 2021-11-04 | METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024192703A Division JP2025016670A (ja) | 2020-11-05 | 2024-11-01 | アテローム硬化性心血管疾患をＬＰＡ標的ＲＮＡｉ構築体により処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023549115A JP2023549115A (ja) | 2023-11-22 |
| JP2023549115A5 true JP2023549115A5 (enExample) | 2024-11-12 |
| JP7798881B2 JP7798881B2 (ja) | 2026-01-14 |
Family
ID=78819940
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526961A Active JP7798881B2 (ja) | 2020-11-05 | 2021-11-04 | アテローム硬化性心血管疾患をＬＰＡ標的ＲＮＡｉ構築体により処置する方法 |
| JP2024192703A Pending JP2025016670A (ja) | 2020-11-05 | 2024-11-01 | アテローム硬化性心血管疾患をＬＰＡ標的ＲＮＡｉ構築体により処置する方法 |
| JP2026071764A Pending JP2026116347A (ja) | 2020-11-05 | 2026-04-23 | アテローム硬化性心血管疾患をＬＰＡ標的ＲＮＡｉ構築体により処置する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024192703A Pending JP2025016670A (ja) | 2020-11-05 | 2024-11-01 | アテローム硬化性心血管疾患をＬＰＡ標的ＲＮＡｉ構築体により処置する方法 |
| JP2026071764A Pending JP2026116347A (ja) | 2020-11-05 | 2026-04-23 | アテローム硬化性心血管疾患をＬＰＡ標的ＲＮＡｉ構築体により処置する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230405040A1 (enExample) |
| EP (1) | EP4240855A1 (enExample) |
| JP (3) | JP7798881B2 (enExample) |
| KR (1) | KR20230104200A (enExample) |
| CN (1) | CN116456990A (enExample) |
| AU (1) | AU2021373780A1 (enExample) |
| CA (1) | CA3199678A1 (enExample) |
| IL (1) | IL302330A (enExample) |
| JO (1) | JOP20230093A1 (enExample) |
| MX (1) | MX2023005198A (enExample) |
| TW (1) | TW202233837A (enExample) |
| WO (1) | WO2022098841A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
| US20250034561A1 (en) * | 2021-02-18 | 2025-01-30 | Oneglobe Holdings Limited | Novel Compositions for Conjugating Oligonucleotides and Carbohydrates |
| CN115851723B (zh) * | 2022-10-24 | 2023-10-03 | 厦门甘宝利生物医药有限公司 | 一种抑制lpa基因表达的rna抑制剂及其应用 |
| US20240226049A1 (en) * | 2023-01-09 | 2024-07-11 | Esperion Therapeutics, Inc. | Methods of treatment using bempedoic acid |
| KR20250131826A (ko) * | 2023-01-13 | 2025-09-03 | 일라이 릴리 앤드 캄파니 | 치료 올리고뉴클레오티드-함유 제약 조성물 및 그를 사용한 투여 요법 |
| CN120693405A (zh) * | 2023-02-03 | 2025-09-23 | 诺华股份有限公司 | 降低一级预防受试者中重大不良心血管事件风险的方法 |
| WO2024240230A1 (zh) * | 2023-05-24 | 2024-11-28 | 南京明德新药研发有限公司 | 双链sirna、其缀合物及其应用 |
| WO2025082058A1 (zh) * | 2023-10-16 | 2025-04-24 | 润佳(上海)医药技术有限公司 | 一种抑制LPA基因表达的dsRNA及其用途 |
| WO2025252223A1 (zh) * | 2024-06-07 | 2025-12-11 | 迈威(上海)生物科技股份有限公司 | 一种抑制PCSK9基因表达的RNAi制剂及其应用 |
| WO2026026890A1 (zh) * | 2024-07-31 | 2026-02-05 | 前沿生物药业(南京)股份有限公司 | 用于抑制LPA基因表达的siRNA及其修饰物与应用 |
| WO2026133253A1 (en) | 2024-12-20 | 2026-06-25 | Novartis Ag | Combinations of antisense agents, pharmaceutical compositions and methods of use |
| CN122511931A (zh) | 2025-02-04 | 2026-08-04 | 丰田纺织株式会社 | 燃料电池系统 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| JP4335310B2 (ja) | 1995-06-07 | 2009-09-30 | ザ ユニバーシティ オブ ブリティッシュ コロンビア | 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用 |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| WO1999001579A1 (en) | 1997-07-01 | 1999-01-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
| US7491805B2 (en) | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| US20030130186A1 (en) | 2001-07-20 | 2003-07-10 | Chandra Vargeese | Conjugates and compositions for cellular delivery |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| CA2487274A1 (en) | 2002-05-06 | 2003-11-13 | Nucleonics Inc. | Spermine chemically linked to lipids and cell-specific targeting molecules as a transfection agent |
| US8017762B2 (en) | 2003-04-17 | 2011-09-13 | Alnylam Pharmaceuticals, Inc. | Modified iRNA agents |
| US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
| WO2008131419A2 (en) | 2007-04-23 | 2008-10-30 | Alnylam Pharmaceuticals, Inc. | Glycoconjugates of rna interference agents |
| EP2229186A2 (en) | 2007-12-04 | 2010-09-22 | Alnylam Pharmaceuticals Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| AR090905A1 (es) | 2012-05-02 | 2014-12-17 | Merck Sharp & Dohme | Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica |
| WO2014205451A2 (en) | 2013-06-21 | 2014-12-24 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| AU2016332900C1 (en) | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| JOP20160211B1 (ar) * | 2015-10-01 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
| JOP20170057B1 (ar) | 2016-03-07 | 2022-03-14 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة كمركبات علاجية |
| JOP20170056B1 (ar) * | 2016-09-02 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة |
| CN119120476A (zh) * | 2017-11-13 | 2024-12-13 | 赛伦斯治疗有限责任公司 | 用于抑制细胞中lpa的表达的核酸 |
| HRP20250277T1 (hr) * | 2017-12-01 | 2025-05-09 | Suzhou Ribo Life Science Co., Ltd. | Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba |
| EP3616724A1 (en) * | 2018-08-27 | 2020-03-04 | SmartDyeLivery GmbH | Pkc inhibitors for the treatment of septic cholestasis with ctm targeting |
| SG11202105900UA (en) * | 2018-12-10 | 2021-07-29 | Amgen Inc | CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF |
-
2021
- 2021-11-04 KR KR1020237018395A patent/KR20230104200A/ko active Pending
- 2021-11-04 AU AU2021373780A patent/AU2021373780A1/en active Pending
- 2021-11-04 CA CA3199678A patent/CA3199678A1/en active Pending
- 2021-11-04 US US18/035,198 patent/US20230405040A1/en active Pending
- 2021-11-04 TW TW110141087A patent/TW202233837A/zh unknown
- 2021-11-04 WO PCT/US2021/058012 patent/WO2022098841A1/en not_active Ceased
- 2021-11-04 EP EP21816592.6A patent/EP4240855A1/en active Pending
- 2021-11-04 CN CN202180074587.9A patent/CN116456990A/zh active Pending
- 2021-11-04 JP JP2023526961A patent/JP7798881B2/ja active Active
- 2021-11-04 IL IL302330A patent/IL302330A/en unknown
- 2021-11-04 MX MX2023005198A patent/MX2023005198A/es unknown
-
2023
- 2023-05-03 JO JOJO/P/2023/0093A patent/JOP20230093A1/ar unknown
-
2024
- 2024-11-01 JP JP2024192703A patent/JP2025016670A/ja active Pending
-
2026
- 2026-04-23 JP JP2026071764A patent/JP2026116347A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6028142B2 (ja) | ヒトアポリポタンパク質ｂと相補的なアンチセンスオリゴヌクレオチドの投与 | |
| Brunner et al. | Clinical use of an orally acting converting enzyme inhibitor: captopril. | |
| Doyon et al. | The use of glucagon in a case of calcium channel blocker overdose | |
| JP2019531357A5 (enExample) | ||
| JP2025504863A5 (enExample) | ||
| Weiler et al. | Serious adverse reactions to protamine sulfate: are alternatives needed? | |
| JP2018203747A5 (enExample) | ||
| FI3529360T3 (fi) | Menetelmiä sydän- ja verisuonitapahtumien ennaltaehkäisemiseksi proproteiini-konvertaasi-subtilisiini-keksiini tyyppi 9 (pcsk9) -proteiinia vähentämällä | |
| Biberstein et al. | Use of β-blockade and hemoperfusion for acute theophylline poisoning | |
| JP2007500741A (ja) | 一時的処置のための短い半減期を有するｃ１インヒビター | |
| JPH06157343A (ja) | ある種の疾病の予防および治療用医薬を製造するためのカリクレインインヒビターの使用 | |
| Wierzbicki | Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention? | |
| US20210093628A1 (en) | Tesofensine and metoprolol for treatment of hypertension | |
| US5021239A (en) | Use of M-CSF to improve lipoprotein cholesterol profiles | |
| AU2019439626A1 (en) | Therapeutic uses of dulaglutide | |
| Bracht et al. | Cyclosporine A and control of vascular tone in the human forearm: influence of post-transplant hypertension | |
| Schlueter et al. | Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein (a) by fosinopril | |
| CN102149376B (zh) | 症状性心力衰竭的长期治疗 | |
| Van Uum et al. | Successful haemodialysis in sotalol-induced torsade de pointes in a patient with progressive renal failure. | |
| Fernández-Ruiz | Low-dose colchicine shows promise in chronic coronary disease | |
| JPH0780765B2 (ja) | ショック状態の治療のための医薬組成物 | |
| Lefer et al. | Mechanism of the lack of a beneficial response to inotropic drugs in hemorrhagic shock | |
| Lim | Benefit of controlling heart rhythm soon after AF diagnosis | |
| JP2001058949A (ja) | 抗ショック剤 | |
| JP2026502533A (ja) | 治療用オリゴヌクレオチド含有医薬組成物及びそれを用いる投与レジメン |